Netramark Holdings Inc · TSX:AIAI
Netramark — Investor Presentation (June 2023)
28 slides from Netramark's investor presentation, June 2023
Slide 1: Corporate Presentation
CSE: AIAI CORPORATE PRESENTATION OTCQB: AINMF June 2023 FRA: 8TV
Slide 2: Disclaimer
IMPORTANT – YOU MUST READ THE FOLLOWING BEFORE CONTINUING: The information contained in this CAUTIONARY NOTE REGARDING FUTURE-ORIENTED FINANCIAL INFORMATION: To the extent any forward-looking statement presentation has been prepared by NetraMark Holdings Inc. (“NetraMark” or the “Company”) and conta
Slide 3: Risk Factors
RISK FACTORS: There are a number of risk factors as set out below that could cause future results of the Company to differ materially from those described herein. The risks and uncertainties described herein are not the only ones the Company faces. Additional risks and uncertainties, including those
Slide 4: Who We Are
The NetraMark vision is to have a material impact on the current 12% clinical trial success rate and serve the pharmaceutical WHO WE ARE industry’s demands for the efficient development of novel therapeutics and medicines. CSE: AIAI OTCQB: AINMF FRA: 8TV
Slide 5: The Team
We have assembled a highly experienced leadership team George Achilleos Josh Spiegel Dr. Joseph Geraci Chief Executive Officer President Chief Technology Officer / Chief Scientific Officer and Director George is a seasoned Business Executive with 25+ years 25-plus years of experience in finance, sal
Slide 6: The AI pharmaceutical space
The AI pharmaceutical space Two key problems to address: THE INDUSTRY 1. There is a real challenge identifying molecules that address disease 2. There is a very low rate of success getting through the clinical trial process CSE: AIAI OTCQB: AINMF FRA: 8TV
Slide 7: The bulk of the headlines are in molecule discovery
1 2 The bulk of the headlines are in molecule discovery 3 THE INDUSTRY • This problem typically requires the ingestion of massive data sets to aid in 4 the discovery of new molecules 4 1) https://pharmaphorum.com/news/verge-genomics-takes-ai-sourced-drug-for-als-into-clinic/ CSE: AIAI 2) https://www
Slide 8: The Opportunity
We believe there is significant opportunity to improve the clinical trial process BASIC DRUG PRE- FDA POST-APPROVAL CLINICAL TRIALS RESEARCH & RESEARCH DISCOVERY CLINICAL REVIEW MONITORING PHASE I PHASE II PHASE III PHASE IV THE OPPORTUNITY From drug discovery through FDA approval, developing a new
Slide 9: The clinical trial market is robust, growing and large
The clinical trial market is robust, growing and large The number of cumulative clinical trials over time1 R&D expenditures (in USD Billions)2 450,000 90.0 399,522 83.0 400,000 80.0 362,500 350,000 325,771 70.0 293,254 300,000 60.0 59.6 262,299 250,000 233,124 50.0 50.7 205,335 200,000 181,227 40.0
Slide 10: The challenge of using AI for clinical trials
The challenge of using AI for clinical trials THE CHALLENGE The challenge centers around the ability to apply AI methods to small datasets and extract statistically significant insights that can be utilized to enrich future studies CSE: AIAI CSE: AIAI OTC: AINMF OTCQB: AINMF FRA: 8TV FRA: 8TV
Slide 11: Over 95% of trials have less than 1,000 participants
Over 95% of trials have less than 1,000 participants Extracting statistically relevant findings from smaller population data sets to provide actionable insights for clinical trials is challenging. NE Cumulative # of trials by anticipated # of participants (1999 – 2021)* OG TTHHEE CSHOALLULTEIN 1-100
Slide 12: Clinical trial offering
THE NETRAMARK APPROACH Clinical trial offering The pharmaceutical industry is looking for novel and proprietary ways to leverage data to help de-risk clinical trials by better directing efforts to enrich future clinical trial studies. CSE: AIAI OTCQB: AINMF FRA: 8TV
Slide 13: Introducing NetraAI
Introducing NetraAI • Built on proprietary AI algorithms developed by Dr. Joseph Geraci THE NETRAMARK APPROACH • Outputs explainability of the influential variables underlying discovered subpopulations • Derives insights delineating interconnections among variables, the response, and the disease sta
Slide 14: The NetraAI difference
Pancreatic Cancer treatment study Patient numbers in the dataset* Complete Response Partial Response Stable Disease Progressive Disease Totals Treatment Groups 1 70 98 49 218 FFX** 0 41 55 33 129 The NetraAI difference GnP*** 1 29 43 16 89 Perspective 1 - NetraMap NetraAI is a unique machine learnin
Slide 15: Introducing NetraGPT
Introducing NetraGPT • Output reports that begin to assemble in seconds and conclude within minutes • Improved explainability of the influential variables THE NETRAMARK APPROACH underlying discovered subpopulations • Additional insights delineating interconnections among variables, the response, and
Slide 16: The NetraMark difference
The NetraMark difference THE NETRAMARK APPROACH CSE: AIAI OTCQB: AINMF FRA: 8TV
Slide 17: The Validation
Dr. Joseph Geraci was recognized Reference: Placebo Response Propensity Scale (PRPS) Scores and for research on placebo response Probability of Placebo Response by Disease Severity related to mental health. Robert Morlock, PhD1 , Joseph Geraci, PhD2 1YourCareChoice, Ann Arbor, MI USA. 2NetraPharma;
Slide 18: The Testimonials
From pharmaceutical clients, strategic partners and advisors “We need personalized, economically accessible and “NetraMark’s capacity to identify insights from small datasets has intelligently designed therapies in neurology and oncology. been particularly useful for my work. My focus has been to fi
Slide 19: The Value
The Value De-risk and Increase the Efficiency of Clinical Trials Our machine learning methodologies are intended to accelerate traditional drug development through improved understanding of the underlying disease and mechanism of action with the expectation for improved clinical trial designs showca
Slide 20: The Target Engagement
The Target Engagement Biotech or pharma company programs with clinical data in an indication of experience in these areas: THE NETRAMARK APPROACH • Oncology • Neurology • Psychiatry • Metabolic • Rare & Orphan Disorders Leverage high level relationships & attend disease specific conferences to engag
Slide 21: NetraAI Initial Customer Assessment
NetraAI Initial Customer Assessment • Entry level paid engagement model for Early Trial Phase • Consultive report deliverable that maximizes learnings from upcoming pre pivotal study to de-risk expensive later THE NETRAMARK APPROACH stage of clinical trial • NetraAI evaluates existing Phase I data,
Slide 22: NetraAI Pivotal Decision Support Solution
NetraAI Pivotal Decision Support Solution • Premium value engagement The role of NetraAI • Pre-pivotal – Phase II complete * THE NETRAMARK APPROACH • Comprehensive recommendations and analysis to support pivotal study plan • Create patient stratification datasets to inform enrichment criteria and em
Slide 23: NetraPlay Access and Support
NETRAPLAY NetraPlay Access and Support • Study specific subscription engagement • Populated with data from previous clinical studies and THE NETRAMARK APPROACH Netra Health Atlas • Ability for biotech/pharma discovery teams to further confirm MOA • Visualize and determine causal factors driving trea
Slide 24: The Revenue Model
Current Year THE REVENUE MODEL The Model Leverage leadership pharmaceutical network Pharma Targeting outreach Aggressive conference schedule Projected Contracted Value ~ $2 - 3M CDN Sales Pipeline Build to $5M+ The information set out above is based on a number of assumptions including that the Comp
Slide 25: The Pharmaceutical AI sector is producing high valuation multiples
The Pharmaceutical AI sector is producing high valuation multiples Comparison Estimated Revenue Pre-Money Valuation Valuation / Rev Multiple Owkin1 2020 ~ $12.15M Nov 2021 ~ $1.12B ~ 92X ConcertAI1 2022 ~ $53M Mar 2022 ~ $1.75B ~ 33X THE MARKET COMPS GNS Healthcare2 ~ $14M Jan 2020 ~ $120M ~ 8.6X Pa
Slide 26: The Advisors & Board
We are supported by experts with extensive experience in technology, neuroscience, mental health, and capital markets. Kevin Taylor Sheetal Jaitly Gino DeMichele Andrew Parks Dr. Joseph Geraci THE ADVISORS & BOARAD Director and Chairman of the Director Director Director Director Board BOARD Seasoned
Slide 27: Thank you
Thank you For more information, please contact george@netramark.com CSE: AIAI OTCQB: AINMF FRA: 8TV
Slide 28: Statutory Rights of Action
STATUTORY RIGHTS OF ACTION In certain circumstances, purchasers resident in certain provinces of Canada, are provided with a remedy for rescission or damages, and (g) in no case will the amount recoverable in such action exceed the price at which the securities were sold to you. The foregoing is or
NetraMark Holdings — Investor Presentation (June 2023) on 6ix